News
AstraZeneca PLC - AZ: positive CHMP for Tagrisso first-line nsclc
RNS Number: 4180 M AstraZeneca PLC 27 April 2018. 27 April 2018 12:30 BST. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "This positive recommendation acknowledges Tagrisso's potential as a new 1st- line standard of care for patients with EGFR-mutated NSCLC in Europe.
RNS Number: 4180 M AstraZeneca PLC 27 April 2018. 27 April 2018 12:30 BST. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "This positive recommendation acknowledges Tagrisso's potential as a new 1st- line standard of care for patients with EGFR-mutated NSCLC in Europe.